Clinical Trial Update: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating surufatinib plus toripalimab for advanced neuroendocrine carcinoma is underway, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Advanced Neuroendocrine Carcinoma | Phase 3 | Status: UNKNOWN